Latest News and Press Releases
Want to stay updated on the latest news?
-
DURHAM, N.C., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
-
DURHAM, N.C., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
-
DURHAM, N.C., Nov. 18, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
-
DURHAM, N.C., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
-
- Dr. Richard D. Katz Joined as Chief Financial Officer -- Raised Gross Proceeds of $50 million in Follow-on Offering - - First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in HIV --...
-
DURHAM, N.C., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
-
DURHAM, N.C., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
-
DURHAM, N.C., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...
-
Two advanced kidney cancer patients from a Phase 2 clinical trial maintain ongoing control of metastatic disease seven years after initiation of treatment with AGS-003 in combination with sunitinib....
-
DURHAM, N.C., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized...